Axsome Therapeutics, Inc. – LSE:0HKF.L
Axsome Therapeutics stock price today
Axsome Therapeutics stock price monthly change
Axsome Therapeutics stock price quarterly change
Axsome Therapeutics stock price yearly change
Axsome Therapeutics key metrics
Market Cap | 4.28B |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -6.38 |
Revenue | 251.02M |
EBITDA | -304.10M |
Income | -296.37M |
Revenue Q/Q | -20.69% |
Revenue Y/Y | 73.58% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -121.14% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAxsome Therapeutics stock price history
Axsome Therapeutics stock forecast
Axsome Therapeutics financial statements
| Jun 2023 | 46.7M | -67.17M | -143.83% |
|---|---|---|---|
| Sep 2023 | 57.79M | -62.19M | -107.62% |
| Dec 2023 | 71.53M | -98.65M | -137.92% |
| Mar 2024 | 74.99M | -68.35M | -91.14% |
| Sep 2025 | 167.96M | -6.21M | -3.7% |
|---|---|---|---|
| Dec 2025 | 220.00M | 30.72M | 13.96% |
| Mar 2026 | 226.31M | 29.73M | 13.14% |
| Jun 2026 | 293.18M | 72.29M | 24.66% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 611638000 | 332.83M | 54.42% |
|---|---|---|---|
| Sep 2023 | 600857000 | 331.34M | 55.15% |
| Dec 2023 | 588236000 | 397.25M | 67.53% |
| Mar 2024 | 545728000 | 401.69M | 73.61% |
| Jun 2023 | -55.34M | -133K | 246.08M |
|---|---|---|---|
| Sep 2023 | -53.54M | -371K | 33.37M |
| Dec 2023 | -30.36M | -7K | -2K |
| Mar 2024 | -53.46M | -98K | -1.18M |
Axsome Therapeutics alternative data
| Aug 2023 | 393 |
|---|---|
| Sep 2023 | 422 |
| Oct 2023 | 422 |
| Nov 2023 | 422 |
| Dec 2023 | 502 |
| Jan 2024 | 502 |
| Feb 2024 | 502 |
| Mar 2024 | 545 |
| Apr 2024 | 545 |
| May 2024 | 545 |
| Jun 2024 | 569 |
| Jul 2024 | 569 |
Axsome Therapeutics other data
| Insider | Compensation |
|---|---|
| Dr. Herriot Tabuteau M.D. (1968) Founder, Chairman, Chief Executive Officer & Pres | $761,250 |
Mr. Nick Pizzie CPA, M.B.A. (1975) Chief Financial Officer | $520,000 |
| Mr. David C. Marek (1965) Chief Commercial Officer | $424,330 |
Dr. Amanda Jones Pharm.D. Senior Vice President of Clinical Research | |
| Mr. Mark L. Jacobson Chief Operating Officer & Sec. | |
Dr. Cedric O'Gorman M.B.A., M.D., MBA Senior Vice President of Clinical Devel. & Medical Affairs | |
Joseph Debrah-Afful CPA, M.B.A. Director of Fin. |
-
What's the price of Axsome Therapeutics stock today?
One share of Axsome Therapeutics stock can currently be purchased for approximately $3.35.
-
When is Axsome Therapeutics's next earnings date?
Unfortunately, Axsome Therapeutics's (0HKF.L) next earnings date is currently unknown.
-
Does Axsome Therapeutics pay dividends?
No, Axsome Therapeutics does not pay dividends.
-
How much money does Axsome Therapeutics make?
Axsome Therapeutics has a market capitalization of 4.28B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 440.8% to 270.6M US dollars.
-
What is Axsome Therapeutics's stock symbol?
Axsome Therapeutics, Inc. is traded on the LSE under the ticker symbol "0HKF.L".
-
What is Axsome Therapeutics's primary industry?
Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
-
How do i buy shares of Axsome Therapeutics?
Shares of Axsome Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Axsome Therapeutics's key executives?
Axsome Therapeutics's management team includes the following people:
- Dr. Herriot Tabuteau M.D. Founder, Chairman, Chief Executive Officer & Pres(age: 57, pay: $761,250)
- Mr. Nick Pizzie CPA, M.B.A. Chief Financial Officer(age: 50, pay: $520,000)
- Mr. David C. Marek Chief Commercial Officer(age: 60, pay: $424,330)
- Dr. Amanda Jones Pharm.D. Senior Vice President of Clinical Research
- Mr. Mark L. Jacobson Chief Operating Officer & Sec.
- Dr. Cedric O'Gorman M.B.A., M.D., MBA Senior Vice President of Clinical Devel. & Medical Affairs
- Joseph Debrah-Afful CPA, M.B.A. Director of Fin.
-
Is Axsome Therapeutics founder-led company?
Yes, Axsome Therapeutics is a company led by its founder Dr. Herriot Tabuteau M.D..
-
How many employees does Axsome Therapeutics have?
As Jul 2024, Axsome Therapeutics employs 569 workers, which is 4% more then previous quarter.
-
When Axsome Therapeutics went public?
Axsome Therapeutics, Inc. is publicly traded company for more then 7 years since IPO on 29 Jan 2018.
-
What is Axsome Therapeutics's official website?
The official website for Axsome Therapeutics is axsome.com.
-
Where are Axsome Therapeutics's headquarters?
Axsome Therapeutics is headquartered at 22 Cortlandt Street, New York, NY.
-
How can i contact Axsome Therapeutics?
Axsome Therapeutics's mailing address is 22 Cortlandt Street, New York, NY and company can be reached via phone at +212 3323241.
Axsome Therapeutics company profile:
Axsome Therapeutics, Inc.
axsome.comLSE
607
Medical - Pharmaceuticals
Healthcare
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
New York, NY 10007
:
ISIN: US05464T1043
:
